Table 1 Patient characteristics.
Donor for the second SCT | ||||
|---|---|---|---|---|
Same donor (n = 163) | Different matched donor (n = 305) | Haplo-identical (n = 88) | P value | |
Age at SCT2 (years, range) | 46 (20–73) | 48 (20–69) | 45 (20–71) | 0.40 |
Gender (male) | 52% | 51% | 41% | 0.67 |
Secondary AML | 16% | 16% | 15% | 0.97 |
Cytogenetics | ||||
Good | 5% | 3% | 1% | 0.009 |
Intermediate | 46% | 39% | 26% | |
Poor | 18% | 15% | 23% | |
Missing | 31% | 43% | 50% | |
Conditioning SCT1 | ||||
MAC | 65% | 66% | 64% | 0.90 |
RIC | 35% | 34% | 36% | |
Donor SCT1 | ||||
Sib | 69% | 45% | 51% | <0.001 |
UD | 31% | 55% | 49% | |
10/10 | 81% | 78% | 62% | |
≤9/10 | 19% | 22% | 38% | |
aGVHD after SCT1 | 22.8% | 15.7% | 20.9% | 0.15 |
cGVHD after SCT1 | 26.2% | 26.8% | 23.9% | 0.89 |
Time SCT1 → relapse (months, range) | 10.6 (1-129.9) | 12.5 (0.6-236.2) | 9.3 (1.1-80.8) | 0.14 |
Time <6 months | 36% | 28% | 35% | 0.13 |
Time relapse → SCT2 | 2.8 (0.5-11.5) | 3.7 (0.5-11.5) | 3.5 (0.7–9.7) | <0.001 |
Time SCT1 → SCT2 | 14.3 (1.7-134.8) | 17.5 (1.9-244.5) | 13.8 (3.1-88.2) | 0.03 |
Donor SCT1/ SCT2 | Sib/Sib (n = 112) UD/UD (n = 51) | Sib/d-Sib (n = 44) Sib/UD (n = 93) UD/d-UD (n = 168) New UD 10/10 77% ≤ 9/10 23% | Sib/haplo (n = 45) UD/haplo (n = 43) | |
Donor gender (male) | 66% | 64% | 64% | 0.84 |
F → M | 19% | 15% | 14% | 0.52 |
Patient CMV (pos) | 66% | 61% | 72% | 0.18 |
Donor CMV (pos) | 58% | 45% | 59% | 0.02 |
Disease status SCT2 | ||||
CR2 | 45% | 45% | 44% | 0.96 |
Active leukemia | 56% | 55% | 56% | |
KPS at SCT2 < 90 | 53% | 44% | 27% | 0.001 |
Conditioning SCT2 | ||||
MAC | 45% | 39% | 40% | 0.48 |
RIC | 55% | 61% | 60% | |
in vivo TCD | 24% | 68% | 30% | <0.001 |
Year of SCT2 | 2011 (2006–2016) | 2013 (2006–2016) | 2014 (2006–2016) | <0.001 |
